<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05047341</url>
  </required_header>
  <id_info>
    <org_study_id>SHR0302-107</org_study_id>
    <nct_id>NCT05047341</nct_id>
  </id_info>
  <brief_title>A Study of Human Substance Balance and Biotransformation of [14C]SHR0302</brief_title>
  <official_title>A Clinical Trial of the Absorption, Metabolism and Excretion of [14C]SHR0302 in Healthy Chinese Adult Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is being conducted to evaluate the absorption, metabolism and excretion of&#xD;
      [14C]SHR0302 in healthy Chinese adult male subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 7, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Actual">September 19, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This is a single-arm and open-label drug interaction study.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>day 1 to day 11</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t</measure>
    <time_frame>day 1 to day 11</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-∞</measure>
    <time_frame>day 1 to day 11</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax</measure>
    <time_frame>day 1 to day 11</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>t1/2</measure>
    <time_frame>day 1 to day 11</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>CL/F</measure>
    <time_frame>day 1 to day 11</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Vz/F</measure>
    <time_frame>day 1 to day 11</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The incidence and severity of adverse events/serious adverse events</measure>
    <time_frame>from ICF signing date to approximate day 11</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Rheumatoid Arthritis (RA)</condition>
  <arm_group>
    <arm_group_label>Single arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR0302、[14C]SHR0302</intervention_name>
    <description>8 mg SHR0302/ 80 µCi [14C]SHR0302, once, D1</description>
    <arm_group_label>Single arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Voluntarily sign the informed consent form, communicate well with the investigator and&#xD;
             be able to complete the trial in strict compliance with the protocol;&#xD;
&#xD;
          2. Chinese male subjects judged by the investigator to be healthy;&#xD;
&#xD;
          3. Adults aged 18 to 45 years (including both ends of the spectrum, as at the time of&#xD;
             signing the informed consent form);&#xD;
&#xD;
          4. Weight ≥ 50 kg and a body mass index (BMI) in the range of 19 to 26 kg/m2 (both ends&#xD;
             inclusive).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Ancillary examinations :&#xD;
&#xD;
          1. Abnormalities in physical examination, vital signs, routine laboratory tests (complete&#xD;
             blood cell analysis, blood biochemistry, coagulation, urine routine, stool routine +&#xD;
             occult blood), thyroid function, 12-lead ECG, chest CT, abdominal ultrasound (liver,&#xD;
             gallbladder, pancreas, spleen and kidney) and other tests of clinical significance.&#xD;
&#xD;
          2. Resting corrected QT interval (QTcF) &gt;450 ms obtained on a 12-lead ECG.&#xD;
&#xD;
          3. Positive for hepatitis B surface antigen or E antigen, hepatitis C antibody, HIV&#xD;
             antibody and syphilis antibody.&#xD;
&#xD;
          4. Screening for novel coronavirus infection with clinically significant abnormal&#xD;
             C-reactive protein or positive novel coronavirus nucleic acid.&#xD;
&#xD;
             Medication history：&#xD;
&#xD;
          5. Systemic use of any drug that inhibits or induces CYP3A within 30 days prior to the&#xD;
             screening period (e.g., inducers - bosentan, paracetamol, efavirenz, etravirine,&#xD;
             phenobarbital, rifampin, mitotane, phenytoin sodium, carbamazepine, apatamide, etc.;&#xD;
             inhibitors - -erythromycin, clarithromycin, fluconazole, ketoconazole, itraconazole,&#xD;
             posaconazole, voriconazole, ciprofloxacin, diltiazem, fluvoxamine, nelfinavir,&#xD;
             conivaptan, aripitant, crizotinib, imatinib, dronedarone, cyclosporine).&#xD;
&#xD;
          6. Have used any prescription drugs, over-the-counter medicines, herbal remedies or&#xD;
             dietary supplements such as vitamins, calcium supplements within 14 days prior to the&#xD;
             screening period.&#xD;
&#xD;
             Medical and surgery history：&#xD;
&#xD;
          7. History of any clinically significant illness or disease or condition that, in the&#xD;
             opinion of the investigator, may affect the results of the test, including but not&#xD;
             limited to circulatory, respiratory, endocrine, neurological, digestive, urinary or&#xD;
             haematological, immunological, psychiatric and metabolic disorders.&#xD;
&#xD;
          8. History of organic heart disease, heart failure, myocardial infarction, angina&#xD;
             pectoris, unexplained arrhythmias, torsional ventricular tachycardia, ventricular&#xD;
             tachycardia, atrioventricular block, QT prolongation syndrome or symptoms of QT&#xD;
             prolongation syndrome and family history (indicated by genetic evidence or sudden&#xD;
             death of a close relative at a young age due to cardiac causes).&#xD;
&#xD;
          9. Have undergone major surgery within the 6 months prior to the screening period or&#xD;
             where the surgical incision has not fully healed; major surgery includes, but is not&#xD;
             limited to, any surgery with significant risk of bleeding, extended general&#xD;
             anaesthesia, or incisional biopsy or significant traumatic injury.&#xD;
&#xD;
         10. Allergies, such as a known history of allergy to two or more substances; or a&#xD;
             potential allergy to the test drug or its excipients as judged by the investigator.&#xD;
&#xD;
         11. Haemorrhoids or perianal disease with regular/ongoing blood in the stool, irritable&#xD;
             bowel syndrome, inflammatory bowel disease.&#xD;
&#xD;
             Living habits：&#xD;
&#xD;
         12. Habitual constipation or diarrhoea.&#xD;
&#xD;
         13. Alcohol abuse or regular alcohol consumption within the 6 months prior to the&#xD;
             screening period, i.e. more than 14 units of alcohol per week (1 unit = 360 mL of beer&#xD;
             or 45 mL of spirits at 40% alcohol by volume or 150 mL of wine); or an alcohol breath&#xD;
             test result of ≥20 mg/dL at the screening period.&#xD;
&#xD;
         14. Those who smoked more than 5 cigarettes per day or habitually used nicotine-containing&#xD;
             products in the 3 months prior to the screening period and were unable to quit during&#xD;
             the trial.&#xD;
&#xD;
         15. Substance abuse or use of soft drugs (e.g. cannabis) 3 months prior to the screening&#xD;
             period or hard drugs (e.g. cocaine, amphetamines, phencyclidine, etc.) 1 year prior to&#xD;
             the screening period; or a positive urine drug test during the screening period.&#xD;
&#xD;
         16. Habitual consumption of grapefruit juice or excessive amounts of tea, coffee and/or&#xD;
             caffeinated beverages that cannot be abstained from during the trial.&#xD;
&#xD;
             Others：&#xD;
&#xD;
         17. Workers exposed to prolonged radiological conditions; or who have had significant&#xD;
             radiological exposure (≥2 chest/abdominal CTs, or ≥3 other types of X-ray&#xD;
             examinations) or participated in radiopharmaceutical labelling tests within 1 year&#xD;
             prior to the test.&#xD;
&#xD;
         18. People who have a history of needle sickness or blood sickness, have difficulty&#xD;
             collecting blood or cannot tolerate venipuncture blood collection.&#xD;
&#xD;
         19. Participation in any other clinical trial (including clinical trials such as drugs and&#xD;
             devices) within 3 months prior to the screening period.&#xD;
&#xD;
         20. Those who have been vaccinated within 1 month prior to screening or those who are&#xD;
             scheduled to be vaccinated during the trial period.&#xD;
&#xD;
         21. Those who plan to have children or donate sperm during the trial and within 1 year&#xD;
             after completion of the trial, or who do not agree that subjects and their spouses&#xD;
             should use strict contraception during the trial and within 1 year after completion of&#xD;
             the trial (see Annex 1 for details).&#xD;
&#xD;
         22. Those who have lost or donated up to 400 mL of blood within 3 months prior to the&#xD;
             screening period, or those who have received a blood transfusion within 1 month.&#xD;
&#xD;
         23. Subjects who, in the opinion of the investigator, have any factors that make them&#xD;
             unsuitable for this trial.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>the first affiliated hospital of Soochow University</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <zip>215006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 8, 2021</study_first_submitted>
  <study_first_submitted_qc>September 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2021</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

